Active, not recruitingNot applicableNCT05161494
Gait in Rare Diseases
Studying Tuberous Sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Universiteit Antwerpen
- Principal Investigator
- Anna Jansen, MD, PhDUniversity Hospital, Antwerp
- Enrollment
- 70 enrolled
- Eligibility
- 6-25 years · All sexes
- Timeline
- 2022 – 2025
Study locations (1)
- University of Antwerp, Antwerp, Belgium
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05161494 on ClinicalTrials.govOther trials for Tuberous Sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05534672Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis ComplexKatarzyna Kotulska
- RECRUITINGNANCT00001975Study of Skin Tumors in Tuberous SclerosisNational Heart, Lung, and Blood Institute (NHLBI)